ALK and non-small cell lung carcinoma: Another study with 715 NSCLC patients had similar findings, where a subset analysis of patients with EGFR or ALK rearrangements had the lowest proportion of PD-L1(+)/CD8+(+) tumors and highest proportion of PD-L1(−)/CD8+(−) tumors.